**Background of AGBL2 Antibody**
AGBL2 (ATP/GTP-binding protein-like 2), also known as cytosolic carboxypeptidase-like protein 2 (CCP2), is a member of the metallopeptidase M14 family. It functions as a cytosolic enzyme involved in post-translational protein modifications, particularly the removal of C-terminal glutamates from tubulin and other substrates, a process termed "deglutamylation." This activity regulates microtubule dynamics, influencing cellular processes such as cilia formation, neuronal morphogenesis, and intracellular transport.
AGBL2 antibodies are essential tools for studying the expression, localization, and functional roles of AGBL2 in various tissues. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect AGBL2 in biological samples. Research has linked AGBL2 dysregulation to neurodegenerative disorders, cancer, and ciliopathies, highlighting its potential as a therapeutic or diagnostic target. For instance, altered AGBL2 expression may contribute to tubulinopathy-related diseases or tumor progression via disrupted microtubule networks.
Commercial AGBL2 antibodies are typically developed in rabbit or mouse hosts, targeting specific epitopes within the protein’s conserved catalytic domain. Validation includes reactivity assays and knockout controls to ensure specificity. Ongoing studies aim to clarify its substrate diversity and regulatory mechanisms, emphasizing the importance of reliable AGBL2-targeting reagents in both basic and translational research.